TNFα regulates SIRT1 cleavage during ocular autoimmune disease

American Journal of Pathology

Volumn 185, Issue 5, 2015, Pages 1324-1333

  Gardner, Peter J ^a   Yazid, Samia ^a   Chu, Colin J ^a,b   Copland, David A ^b,c   Adamson, Peter ^d   Dick, Andrew D ^a,b,c   Calder, Virginia L ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; SIRT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE UVEITIS; BONE MARROW CELL; CARTILAGE CELL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; ANIMAL; AUTOIMMUNE DISEASE; DISEASE MODEL; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; PATHOLOGY; UVEITIS; WESTERN BLOTTING;

ANIMALS; AUTOIMMUNE DISEASES; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; MICE; SIRTUIN 1; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84928019242     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2015.01.017     Document Type: Article

References (45)

1. M. Feldmann, and R.N. Maini TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases Nat Med 9 2003 1245 1250
2. S.I. Grivennikov, A.V. Tumanov, D.J. Liepinsh, A.A. Kruglov, B.I. Marakusha, A.N. Shakhov, T. Murakami, L.N. Drutskaya, I. Förster, B.E. Clausen, L. Tessarollo, B. Ryffel, D.V. Kuprash, and S.A. Nedospasov Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/neutrophils: protective and deleterious effects Immunity 22 2005 93 104
3. D.J. MacEwan TNF receptor subtype signalling: differences and cellular consequences Cell Signal 14 2002 477 492
4. M. Sade-Feldman, J. Kanterman, E. Ish-Shalom, M. Elnekave, E. Horwitz, and M. Baniyash Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation Immunity 38 2013 541 554
5. F. Yeung, J.E. Hoberg, C.S. Ramsey, M.D. Keller, D.R. Jones, R.A. Frye, and M.W. Mayo Modulation of NF-[kappa]B-dependent transcription and cell survival by the SIRT1 deacetylase EMBO J 23 2004 2369 2380
6. J. Zhang, S.-M. Lee, S. Shannon, B. Gao, W. Chen, A. Chen, R. Divekar, M.W. McBurney, H. Braley-Mullen, H. Zaghouani, and D. Fang The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice J Clin Invest 119 2009 3048 3058
7. J. Sequeira, G. Boily, S. Bazinet, S. Saliba, X. He, K. Jardine, C. Kennedy, W. Staines, C. Rousseaux, R. Mueller, and M.W. McBurney Sirt1-null mice develop an autoimmune-like condition Exp Cell Res 314 2008 3069 3074
8. N.P. Singh, V.L. Hegde, L.J. Hofseth, M. Nagarkatti, and P. Nagarkatti Resveratrol (trans-3,5,4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor Mol Pharmacol 72 2007 1508 1521
9. J.C. Milne, P.D. Lambert, S. Schenk, D.P. Carney, J.J. Smith, D.J. Gagne, L. Jin, O. Boss, R.B. Perni, C.B. Vu, J.E. Bemis, R. Xie, J.S. Disch, P.Y. Ng, J.J. Nunes, A.V. Lynch, H. Yang, H. Galonek, K. Israelian, W. Choy, A. Iffland, S. Lavu, O. Medvedik, D.A. Sinclair, J.M. Olefsky, M.R. Jirousek, P.J. Elliott, and C.H. Westphal Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes Nature 450 2007 712 716
10. P.J. Gardner, L. Joshi, R.W.J. Lee, A.D. Dick, P. Adamson, and V.L. Calder SIRT1 activation protects against autoimmune T cell-driven retinal disease in mice via inhibition of IL-2/Stat5 signaling J Autoimmun 42 2013 117 129
11. A.A. Sauve, C. Wolberger, V.L. Schramm, and J.D. Boeke The biochemistry of sirtuins. Annual Review of Biochemistry 2006 Annual Reviews Palo Alto 435 465
12. H. Huang, and D.J. Tindall Dynamic FoxO transcription factors J Cell Sci 120 2007 2479 2487
13. H. Dai, L. Kustigian, D. Carney, A. Case, T. Considine, B.P. Hubbard, R.B. Perni, T.V. Riera, B. Szczepankiewicz, G.P. Vlasuk, and R.L. Stein SIRT1 activation by small molecules J Biol Chem 285 2010 32695 32703
14. M. Dvir-Ginzberg, V. Gagarina, E.J. Lee, R. Booth, O. Gabay, and D.J. Hall Tumor necrosis factor α-mediated cleavage and inactivation of SirT1 in human osteoarthritic chondrocytes Arthritis Rheum 63 2011 2363 2373
15. D.A. Copland, M.S. Wertheim, W.J. Armitage, L.B. Nicholson, B.J.E. Raveney, and A.D. Dick The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation Invest Ophthalmol Vis Sci 49 2008 5458 5465
16. M.E. Gegg, R. Harry, D. Hankey, H. Zambarakji, G. Pryce, D. Baker, P. Adamson, V. Calder, and J. Greenwood Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction J Immunol 174 2005 2327 2335
17. A.E. Edling, D. Gomes, T. Weeden, J. Dzuris, J. Stefano, C. Pan, J. Williams, J. Kaplan, and M.A. Perricone Immunosuppressive activity of a novel peptide analog of alpha-melanocyte stimulating hormone (α-MSH) in experimental autoimmune uveitis J Neuroimmunol 236 2011 1 9
18. A.D. Dick, P.G. McMenamin, H. Körner, B.J. Scallon, J. Ghrayeb, J.V. Forrester, and J.D. Sedgwick Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina Eur J Immunol 26 1996 1018 1025
19. A.D. Dick, L. Duncan, G. Hale, H. Waldmann, and J. Isaacs Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis J Autoimmun 11 1998 255 264
20. M. Robertson, J. Liversidge, J.V. Forrester, and A.D. Dick Neutralizing tumor necrosis factor-α activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis Invest Ophthalmol Vis Sci 44 2003 3034 3041
21. M. Ramos-Casals, P. Brito-Zerón, M.-J. Soto, M.-J. Cuadrado, and M.A. Khamashta Autoimmune diseases induced by TNF-targeted therapies Best Pract Res Clin Rheumatol 22 2008 847 861
22. A.D. Dick, J.V. Forrester, J. Liversidge, and A.P. Cope The role of tumour necrosis factor (TNF-α) in experimental autoimmune uveoretinitis (EAU) Prog Retin Eye Res 23 2004 617 637
23. D. Atan, J. Heissigerova, L. Kuffová, A. Hogan, D.J. Kilmartin, J.V. Forrester, J.L. Bidwell, A.D. Dick, and A.J. Churchill Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis Mol Vis 19 2013 184 195
24. A. Joseph, D. Raj, H.S. Dua, P.T. Powell, P.C. Lanyon, and R.J. Powell Infliximab in the treatment of refractory posterior uveitis Ophthalmology 110 2003 1449 1453
25. J.R. Smith, P.H. Hart, D.J. Coster, and K.A. Williams Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis Invest Ophthalmol Vis Sci 39 1998 658 661
26. K. Koizumi, V. Poulaki, S. Doehmen, G. Welsandt, S. Radetzky, A. Lappas, N. Kociok, B. Kirchhof, and A.M. Joussen Contribution of TNF-α to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo Invest Ophthalmol Vis Sci 44 2003 2184 2191
27. U.C. Yadav, M. Shoeb, S.K. Srivastava, and K.V. Ramana Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice Invest Ophthalmol Vis Sci 52 2011 8076 8085
28. L. Kasner, C.C. Chan, S.M. Whitcup, and I. Gery The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis Invest Ophthalmol Vis Sci 34 1993 2911 2917
29. J. Rosenbaum, Y. Han, J.M. Park, M. Kennedy, and S. Planck Tumor necrosis factor-alpha is not essential in endotoxin induced eye inflammation: studies in cytokine receptor deficient mice J Rheumatol 25 1998 2408
30. Agarwal R, Silver P, Caspi R: Rodent Models of Experimental Autoimmune Uveitis. Autoimmunity: Methods and Protocols. New York City, NY, Humana Press (Springerlink), 2012, pp 443-469
31. E.C. Kerr, B.J.E. Raveney, D.A. Copland, A.D. Dick, and L.B. Nicholson Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations J Autoimmun 31 2008 354 361
32. H. Xu, A. Manivannan, J. Liversidge, P.F. Sharp, J.V. Forrester, and I.J. Crane Involvement of CD44 in leukocyte trafficking at the blood-retinal barrier J Leukoc Biol 72 2002 1133 1141
33. Z. Zhang, X. Wu, J. Duan, D. Hinrichs, K. Wegmann, G.L. Zhang, M. Hall, and J.T. Rosenbaum Low dose rapamycin exacerbates autoimmune experimental uveitis PLoS One 7 2012 e36589
34. D. Luger, P.B. Silver, J. Tang, D. Cua, Z. Chen, Y. Iwakura, E.P. Bowman, N.M. Sgambellone, C.-C. Chan, and R.R. Caspi Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category J Exp Med 205 2008 799 810
35. S. Hoey, P.S. Grabowski, S.H. Ralston, J.V. Forrester, and J. Liversidge Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-gamma-dependent mechanism J Immunol 159 1997 5132 5142
36. M.R. Anderson, and M. Tary-Lehmann Staphylococcal enterotoxin-B-induced lethal shock in mice is T-cell-dependent, but disease susceptibility is defined by the non-T-cell compartment Clin Immunol 98 2001 85 94
37. N. Allie, S.I. Grivennikov, R. Keeton, N.-J. Hsu, M.-L. Bourigault, N. Court, C. Fremond, V. Yeremeev, Y. Shebzukhov, B. Ryffel, S.A. Nedospasov, V.F.J. Quesniaux, and M. Jacobs Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection Sci Rep 3 2013 1 14
38. L. Xu, H. Yoon, M.Q. Zhao, J. Liu, C.V. Ramana, and R.I. Enelow Cutting Edge: pulmonary immunopathology mediated by antigen-specific expression of TNF-α by antiviral CD8+ T cells J Immunol 173 2004 721 725
39. M. Rossol, U. Meusch, M. Pierer, S. Kaltenhäuser, H. Häntzschel, S. Hauschildt, and U. Wagner Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells J Immunol 179 2007 4239 4248
40. P. LeHoang The gold standard of noninfectious uveitis: corticosteroids Dev Ophthalmol 51 2012 7 28
41. C. Guo, X. Chu, Y. Shi, W. He, L. Li, L. Wang, Y. Wang, J. Peng, and M. Hou Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura J Clin Immunol 27 2007 557 562
42. S. Pichyangkul, D. Schick, W. Schober, G. Dixon, and A. Khan Increased expression of adhesive proteins on leukocytes by TNF alpha Exp Hematol 16 1988 588 593
43. P. Yossuck, Y. Yan, M. Tadesse, and R.D. Higgins Dexamethasone alters TNF-α expression in retinopathy Mol Genet Metab 72 2001 164 167
44. H. Oppenheimer, O. Gabay, H. Meir, A. Haze, L. Kandel, M. Liebergall, V. Gagarina, E.J. Lee, and M. Dvir-Ginzberg 75-kd Sirtuin 1 blocks tumor necrosis factor α-mediated apoptosis in human osteoarthritic chondrocytes Arthritis Rheum 64 2012 718 728
45. L. Li, L. Wang, L. Li, Z. Wang, Y. Ho, T. McDonald, T.L. Holyoake, W. Chen, and R. Bhatia Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib Cancer Cell 21 2012 266 281